|
Tumor Progression
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Currently, it is considered that the extensively expressed of Mcl-1 protein in melanoma cells is associated with rapid tumor progression, poor prognosis and low chemosensitivity.
|
31432325 |
2019 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Overexpression of myeloid cell leukaemia-1 (Mcl-1) and Survivin is associated with drug resistance, tumour progression and inhibition of apoptotic mechanisms in leukaemia and several cancers.
|
29113504 |
2018 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
We have demonstrated that inhibiting MCL-1 is efficacious in suppressing tumour progression in pre-clinical models of breast cancer and revealed that in addition to its role in cell survival, MCL-1 modulated cellular invasion.
|
29166822 |
2018 |
|
Tumor Progression
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Furthermore, Mcl-1 is overexpressed in many invasive bladder carcinomas, and it is related to tumor progression, so Mcl-1 expression may be of predictive value in bladder cancer.
|
30563080 |
2018 |
|
Tumor Progression
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Over-expression of MCL-1 has been closely related to tumor progression as well as to resistance, not only to traditional chemotherapies but also to targeted therapeutics including BCL-2 inhibitors such as ABT-263.
|
27744724 |
2017 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
These results suggested that FBXW7 was associated with cancer progression and mediated sensitivity to gemcitabine and nab-paclitaxel via MCL1 accumulation in pancreatic cancer.
|
29348852 |
2017 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Our studies not only define the essential role of Mcl-1 in chemoresistance, but also for the first time link a key pro-survival Bcl-2 family member with the NOX protein family, both of which have significant ramifications in cancer progression.
|
28423654 |
2017 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
BCL2L1 and MCL1 are key anti-apoptotic genes, and critical for cancer progression.
|
27264345 |
2016 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Mcl-1 dependent tumors did not respond to ABT-199 alone and showed no significant difference in time to tumor progression between chemotherapy alone or ABT-199/cyclophosphamide combination.
|
26874859 |
2016 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Overexpression of myeloid cell leukemia-1 (Mcl-1), an anti-apoptotic protein, is associated with tumor progression and drug resistance in leukemia and several cancers.
|
27049076 |
2016 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Myeloid cell leukemia-1 (Mcl-1) has been implicated in cancer progression and is overexpressed in a variety of human cancers.
|
26058661 |
2015 |
|
Tumor Progression
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
The expression of Mcl-1 is an indicator of tumor progression and postoperative recurrence in patients with gastric carcinoma.
|
15224193 |
2004 |